KINAXIS
11.1.2024 13:01:50 CET | Business Wire | Press release
Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced an expansion of its retail offering with the release of multiple new AI- and ML-powered innovations that provide retailers with end-to-end supply chain transparency, demand forecasting, and powerful simulation scenario planning capabilities to ensure customers can buy the goods they want, when and where they want them, regardless of unforeseen disruptions.
From unpredictable demand spikes driven by changing consumer habits and the rise of omni-channel commerce that seeks to provide a seamless shopping experience across multiple touchpoints, the retail landscape has never been more competitive, with retailers’ supply chains facing countless challenges that threaten their ability to keep customers happy and turn a profit.
Designed to simplify retailers’ ability to successfully manage the complexity of countless locations, SKUs, promotions and inventory variables that demand unparalleled decision-making, Kinaxis’ enhanced retail offering now includes:
- Demand.AI innovations – powerful machine-learning based models tailored to the scale and complexity of retailers that enables better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. social sentiment, weather, shifts in consumer behavior, local/national events) are influencing short and long-term demand for their products, and which can inform actions to maximize revenue opportunities and proactively resolve risks.
- Replenishment Planning – an all-new capability that enables retailers to better manage replenishment parameters across their supply chain to ensure every item at every store and distribution center gets restocked in a timely manner while establishing guardrails to protect stores from shipping excess inventory that would exceed their shelf-life capacity and increase their inventory holding costs.
- Demand Planning innovations – provides retailers with easy-to-interpret visualizations that explain demand patterns while enabling them to make instant adjustments to forecasts based on human insights around trends at any part of their supply chains, by product, geography, store, SKU, day and more.
“Faced with ever increasing consumer expectations, today’s retailers are in desperate need of solutions that enable them to make confident decisions around their supply chains at scale,” said Andrew Bell, chief product officer at Kinaxis. “With these latest innovations, businesses will finally be able to take the guesswork out of demand and replenishment planning with a view to creating a seamless and resilient end-to-end supply chain. And with additional investments on the horizon in promotion planning and allocation, we’re confident that retailers will continue to look to Kinaxis to help them provide their customers with the best products while ensuring their shelves are always fully stocked.”
The new retail-focused product innovations will enable Kinaxis to strengthen its position within the sector including with new customers like sporting goods leader Brooks Running and existing partners like HAVI, one of the world’s foremost experts in supply chain integration. Last year, Kinaxis and HAVI announced they were joining forces to innovate and transform the Quick Service Restaurant industry.
“With the pace of doing business speeding up and consumer behavior changing by the minute, companies can no longer rely on incremental improvements to their supply chain, which is why we were so thrilled to partner with Kinaxis who have proven their mettle for meeting the demanding needs of customers regardless of the industry,” said Rodney Brown, senior vice president and chief supply chain officer, North America and global planning and analytics at HAVI. “We’re eager to roll out these state-of-the-art capabilities to some of our largest customers and anticipate that they will immediately see the value they bring to their overall business.”
With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands across all sectors including CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end to end from strategic planning to last-mile delivery.
Kinaxis’ retail product innovations will be showcased at NRF 2024 from January 14 – 16, 2024, at the Jacob K. Javits Convention Center in New York City. Visit Kinaxis at Booth #4068.
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111554461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
